LILRB1 and plasma cell myeloma: Moreover, peripheral NK cells from multiple myeloma (MM) and prostate cancer patients express markedly higher levels of LILRB1 when compared with those from healthy donors, which may hinder NK tumoricidal effects (41) (Figure 1B).